Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing

@article{Trochet2016ReprogrammingTD,
  title={Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing},
  author={Delphine Trochet and Bernard Prudhon and Arnaud Jollet and Stéphanie Lorain and Marc Bitoun},
  journal={Molecular Therapy. Nucleic Acids},
  year={2016},
  volume={5}
}
Dynamin 2 (DNM2) is a large GTPase, ubiquitously expressed, involved in membrane trafficking and regulation of actin and microtubule cytoskeletons. DNM2 mutations cause autosomal dominant centronuclear myopathy which is a rare congenital myopathy characterized by skeletal muscle weakness and histopathological features including nuclear centralization in absence of regeneration. No curative treatment is currently available for the DNM2-related autosomal dominant centronuclear myopathy. In order… 

Spliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA

Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin

This study highlights an efficient approach to revert the severe form of dynamin-related centronuclear myopathy and reveals that the dynamin conformational switch is key for muscle function and should be targeted for future therapeutic developments.

Efficient system for upstream mRNA trans-splicing to generate covalent, head-to-tail, protein multimers

This plasmid-based trans-splicing system is adaptable to multiple gene delivery systems, and it presents new opportunities for investigating molecular mechanisms of trans- Splicing, generating covalent protein multimers with novel functions within cells, and producing mRNAs encoding large proteins from split precursors.

Allele‐specific silencing therapy for Dynamin 2‐related dominant centronuclear myopathy

Allele‐specific siRNA sequences were developed in order to specifically knock down the human and murine DNM2‐mRNA harbouring the p.R465W mutation without affecting the wild‐type allele.

Common Pathogenic Mechanisms in Centronuclear and Myotubular Myopathies and Latest Treatment Advances

The contribution of the different CNM models to understanding physiopathology and therapy development is reviewed with a focus on the commonly dysregulated pathways and current therapeutic targets.

Centronuclear myopathies under attack: A plethora of therapeutic targets

Different therapeutic strategies that have been tested so far for centronuclear myopathies are reviewed, some of which may be translated to patients.

Recent advances in understanding congenital myopathies

Significant progress in the provision of molecular diagnoses brings important information and value to patients and their families, such as possible disease prognosis, better disease management, and informed reproductive choice.

References

SHOWING 1-10 OF 41 REFERENCES

A Gene Gun-mediated Nonviral RNA trans-splicing Strategy for Col7a1 Repair.

A novel in vivo nonviral RNA therapy approach to restore type VII collagen expression for causative treatment of dystrophic epidermolysis bullosa is described.

Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing.

Results demonstrate that the alternatively spliced SMN2 exon 7 is a tractable target for replacement by trans-splicing in SMA patient fibroblasts.

Dysferlin rescue by spliceosome-mediated pre-mRNA trans-splicing targeting introns harbouring weakly defined 3' splice sites.

A 3' replacement strategy for mutated DYSF pre-mRNAs induced by spliceosome-mediated pre- mRNA trans-splicing (SmaRT) by the use of a PTM is established and rescue of Dysf protein by SmaRT in vivo is demonstrated.

Cis-splicing and translation of the pre-trans-splicing molecule combine with efficiency in spliceosome-mediated RNA trans-splicing.

This work investigated the efficacy of RNA trans-splicing as a mode of RNA therapy for dysferlinopathies and titinopathies that are due to mutations in the Dysferlin (DYSF) and TTN genes in vitro and in vivo and uncovered a possible issue of the technique in the form of undesirable translation of RNA pre-trans-splice molecules, directly from open reading frames present on the molecule or associated with internal alternative cis-splices.

Considerations for a Successful RNA Trans-splicing Repair of Genetic Disorders

Spliceosome-mediated RNA trans-splicing (SMaRT) has emerged as a novel technology for the repair of mutations in monogenic disorders and provides several advantages relative to other gene therapeutic approaches, such as complementary DNA (cDNA) therapy.

Exon Exchange Approach to Repair Duchenne Dystrophin Transcripts

The feasibility of RNA surgery is shown by using a double trans-splicing approach allowing the specific substitution of a given mutated exon and the possibility to fix up mutated exons, refurbish deleted exons and introduce protein motifs, while keeping natural untranslated sequences, which are essential for mRNA stability and translation regulation.

Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches

RNA-based therapeutic approaches using splice-switching oligonucleotides to rescue dystrophin in Duchenne muscular dystrophy preclinical models and are currently being evaluated in DMD patients are applied in vitro, illustrating that a given PTM can be suitable for a variety of mutations.

Repair of Mybpc3 mRNA by 5′-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy

This study provides the first evidence of successful 5′-trans-splicing in vivo and proof-of-concept of mRNA repair in the most prevalent cardiac genetic disease, HCM, and opens new horizons for causal therapy of the severe forms of the disease.

Spliceosome-mediated trans-splicing: the therapeutic cut and paste.

In this review, the progress made toward the medical use of SMaRT is summarized and an outlook on its upcoming applications is provided.

Trans-Splicing-Mediated Improvement in a Severe Mouse Model of Spinal Muscular Atrophy

These results provide the first in vivo demonstration that SMN2 trans-splicing leads to a lessening of the severity of the SMA phenotype and provide evidence for the power of this strategy for reprogramming genetic diseases at the pre-mRNA level.